RxDoctor Payments Data

Leslie Menchetti

Family · Orland, CANPI 1083654677

Payments from drug & device makers

$5,545in general payments, 2019–2025

Across 223 payments — averaging $24.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$718
  • AstraZeneca$656
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$464
  • Lilly USA, LLC$318
  • Pfizer$267
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$5,49999%
  • Education$461%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,545 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide105$98,853
FarxigaDapagliflozin Propanediol86$91,648
JardianceEmpagliflozin46$58,778
XifaxanRifaximin16$50,088
MounjaroTirzepatide43$45,936
EliquisApixaban32$45,582
Nurtec OdtRimegepant Sulfate12$22,675
JanuviaSitagliptin Phosphate26$19,815
RybelsusSemaglutide11$16,627
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$11,659
Combivent RespimatIpratropium/Albuterol Sulfate11$11,547
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$8,672
GemtesaVibegron14$7,786
MyrbetriqMirabegron13$6,888
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$6,691

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$718$115,480116 claims
AstraZenecaFarxiga, Breztri Aerosphere$656$103,307106 claims
Boehringer IngelheimJardiance, Combivent Respimat$100$70,32657 claims
PfizerEliquis, Nurtec Odt$267$68,25644 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$464$50,08816 claims
Lilly USA, LLCMounjaro$318$45,93643 claims
GSKTrelegy Ellipta, Breo Ellipta$145$14,56528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.

Other family in Orland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →